FINHUB Insights

ABT · Q1 FY26 · Jan 1 – Mar 31, 2026

Abbott Laboratories Q1 FY26: where the revenue came from and where it went

Abbott Laboratories Q1 FY26: revenue $11.2B (+8% year over year). Net profit $1.1B. Largest cohort Medical Devices $5.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2026
Reported
Jul 28, 2026 10-Q
Sankey diagram of Abbott Laboratories's income statement for Q1 FY26: revenue of $11.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$11.2B +8% year over year
Gross profit$6.3B 56% margin
Operating profit$1.3B 12% margin
Net profit$1.1B 10% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 11.2 100% +8%
Medical Devices 5.9 53%
Diagnostic Products 3.1 28%
Nutritional Products 2.1 19%
Other 0.1 1%
Cost of revenue−4.944%
Gross profit6.356% margin−1pp
Research & development−0.87%+0pp
SG&A−3.734%+4pp
Other−0.44%+0pp
Operating profit1.312% margin−4pp
Tax−0.3
Net profit1.110%−3pp
Filing on EDGAR More quarters of ABT

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters